Urothelial Cancer Drugs Global Market Report 2024

The global urothelial cancer drugs market has grown exponentially in recent years. It will grow from $2.34 billion in 2023 to $2.84 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The increase during the historical period can be credited to initiatives focused on raising awareness and promoting early detection, educational programs for physicians, support from patient advocacy groups, the advancement of standard care practices, and the identification of biomarkers.

The global urothelial cancer drugs market is expected to see exponential growth in the next few years. It will grow to $5.92 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The projected growth during the forecast period can be linked to progress in diagnostic imaging, the integration of artificial intelligence in drug development, a shift towards patient-centered care, increased investment in research and development, and regulatory modifications. Key trends anticipated in this period involve advancements in imaging technologies, the emphasis on patient-centric care, changes in healthcare reimbursement structures, the utilization of genomic profiling, and the evolution of regulatory frameworks.

The increasing prevalence of urothelial cancer is anticipated to drive the urothelial cancer drug market. Urothelial cancer, associated with urothelial cells lining various organs, necessitates novel drugs and therapies to address the growing incidence of the disease and reduce fatalities. For instance, data from January 2023 provided by the American Cancer Society Inc., a US-based health organization, reveals that approximately 62,420 men and 19,870 women are diagnosed with bladder cancer out of 82,290 new cases. The reported figures also include 16,710 deaths due to bladder cancer, with 4,550 cases among women and 12,160 among men. The rising prevalence of urothelial cancer underscores the need for advancements in urothelial cancer drugs and therapies, driving the market forward.

The increasing demand for chemotherapy is set to propel the growth of the urothelial cancer drugs market. Chemotherapy, a systemic treatment circulating throughout the body via the bloodstream, proves effective against cancer cells that may have spread to distant sites. Its application in urothelial cancer management includes inhibiting cancer cell growth, treating metastatic disease, targeting rapidly dividing cells, and providing palliative care to relieve symptoms and improve patients' quality of life. As reported in February 2022 by Healthcare IT News, the demand for cancer chemotherapy is expected to rise from 10 million to 15 million by 2040, according to the Union for International Cancer Control (UICC). The increasing demand for chemotherapy underscores its crucial role in urothelial cancer treatment, contributing to the growth of the urothelial cancer drugs market.

The rising prevalence of the geriatric population is identified as a significant driver for the urothelial cancer drugs market. Adults aged 65 and older, constituting the geriatric population, are more susceptible to various diseases due to lowered immunity associated with advanced age. The risk of urothelial cancer increases with age, necessitating urothelial cancer drugs for treatment. According to data from October 2022 provided by the World Health Organization, globally, 1 in 6 people will be 60 or older by 2030, and the number of individuals in this age group is expected to double to 2.1 billion by 2050. Similarly, data from June 2021, according to the UK Parliament's House of Commons Library, indicates that the senior population in the UK will comprise 24% of the total population (17.4 million people) by 2043. The rising prevalence of the geriatric population is expected to drive the urothelial cancer drug market as the need for effective treatments for this demographic grows.

The urothelial cancer drug market is witnessing a significant trend towards the development of novel combination therapies. Combination therapy involves the use of two or more therapeutic agents for the treatment of a condition. Major players in the urothelial cancer drug market are strategically focusing on creating combination therapies to strengthen their position. Combining immunotherapy with targeted drugs is particularly attractive in cancer management as it aims to reduce the emergence of resistance and improve treatment response. For instance, a notable development in July 2022 involved the United States Food and Drug Administration (FDA) accepting the biologics license application (BLA) for an IL-15 superagonist, ImmunityBio's N-803, in combination with Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. This combination therapy is designed to be delivered directly to induce natural killer cells and T cells in the bladder, representing an innovative approach in urothelial cancer treatment.

Major companies in the urothelial cancer drugs market are also prioritizing product approvals for combination therapies to drive revenues. One such example is the combination of padcev with Keytruda, a product approved by Astellas Pharma Inc., a Japan-based pharmaceutical company. In April 2023, the FDA granted approval for padcev with Keytruda for the treatment of metastatic urothelial cancer. This combination therapy is recommended as the initial line of treatment when cisplatin-containing chemotherapy is not an option for certain patients with locally advanced or metastatic urothelial carcinoma. Clinical studies have shown that the combination of padcev with Keytruda significantly enhances overall survival and progression-free survival in patients with advanced bladder cancer.

Major companies operating in the urothelial cancer drugs market report are F Hoffmann La Roche AG, The Bristol-Myers Squibb Company, Merck & Co Inc., Pfizer Inc., Genentech Inc., GSK PLC, UroGen Pharma Inc., Johnson & Johnson Inc., Astellas Pharma Inc., Sesen Bio Inc., Gilead Sciences Inc., Seagen Inc., Eisai Co. Ltd., Agensys Inc., AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Janssen Pharmaceuticals Inc., Seattle Genetics Inc., Eli Lilly and Company, Bayer AG, AbbVie Inc., Exelixis Inc., Ipsen Biopharmaceuticals Inc., Millennium Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co. Ltd., Spectrum Pharmaceuticals Inc., Zydus Lifesciences Ltd.

North America was the largest region in the urothelial cancer drugs market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urothelial cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of urothelial cancer include urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. Urothelial carcinoma specifically addresses epithelial tissue tumors, referring to transitional cell cancer occurring near epithelial tissues. Urothelial cancer drugs typically encompass treatment approaches such as immunotherapy, chemotherapy, and preservation therapy, all tailored for managing urothelial cancer. These drugs are distributed through various channels including hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers.

This report provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial cancer drugs market consists of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.